These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 9183139)

  • 1. A pilot study of nadolol for overt aggression in developmentally delayed individuals.
    Connor DF; Ozbayrak KR; Benjamin S; Ma Y; Fletcher KE
    J Am Acad Child Adolesc Psychiatry; 1997 Jun; 36(6):826-34. PubMed ID: 9183139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nadolol to treat aggression and psychiatric symptomatology in chronic psychiatric inpatients: a double-blind, placebo-controlled study.
    Ratey JJ; Sorgi P; O'Driscoll GA; Sands S; Daehler ML; Fletcher JR; Kadish W; Spruiell G; Polakoff S; Lindem KJ
    J Clin Psychiatry; 1992 Feb; 53(2):41-6. PubMed ID: 1347291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study.
    McDougle CJ; Holmes JP; Bronson MR; Anderson GM; Volkmar FR; Price LH; Cohen DJ
    J Am Acad Child Adolesc Psychiatry; 1997 May; 36(5):685-93. PubMed ID: 9136504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donepezil use in children and adolescents with tics and attention-deficit/hyperactivity disorder: an 18-week, single-center, dose-escalating, prospective, open-label study.
    Cubo E; Fernández Jaén A; Moreno C; Anaya B; González M; Kompoliti K
    Clin Ther; 2008 Jan; 30(1):182-9. PubMed ID: 18343255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Open-label use of placebos in the treatment of ADHD: a pilot study.
    Sandler AD; Bodfish JW
    Child Care Health Dev; 2008 Jan; 34(1):104-10. PubMed ID: 18171451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modafinil in children and adolescents with attention-deficit/hyperactivity disorder: a preliminary 8-week, open-label study.
    Boellner SW; Earl CQ; Arora S
    Curr Med Res Opin; 2006 Dec; 22(12):2457-65. PubMed ID: 17257460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physical aggression during admission to a child and adolescent inpatient unit: predictors and impact on clinical outcomes.
    Dean AJ; Duke SG; Scott J; Bor W; George M; McDermott BM
    Aust N Z J Psychiatry; 2008 Jun; 42(6):536-43. PubMed ID: 18465381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy.
    Shinnar S; Pellock JM; Conry JA
    Eur J Paediatr Neurol; 2009 Jan; 13(1):3-9. PubMed ID: 18343174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nadolol plus spironolactone in the prophylaxis of first variceal bleed in nonascitic cirrhotic patients: A preliminary study.
    Abecasis R; Kravetz D; Fassio E; Ameigeiras B; Garcia D; Isla R; Landeira G; Dominguez N; Romero G; Argonz J; Terg R
    Hepatology; 2003 Feb; 37(2):359-65. PubMed ID: 12540786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case series: amantadine open-label treatment of impulsive and aggressive behavior in hospitalized children with developmental disabilities.
    King BH; Wright DM; Snape M; Dourish CT
    J Am Acad Child Adolesc Psychiatry; 2001 Jun; 40(6):654-7. PubMed ID: 11392342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding: a multicenter trial.
    de la Peña J; Brullet E; Sanchez-Hernández E; Rivero M; Vergara M; Martin-Lorente JL; Garcia Suárez C
    Hepatology; 2005 Mar; 41(3):572-8. PubMed ID: 15726659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study.
    Hanania NA; Singh S; El-Wali R; Flashner M; Franklin AE; Garner WJ; Dickey BF; Parra S; Ruoss S; Shardonofsky F; O'Connor BJ; Page C; Bond RA
    Pulm Pharmacol Ther; 2008; 21(1):134-41. PubMed ID: 17703976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rating aggression in the clinical setting. A retrospective adaptation of the Overt Aggression Scale: preliminary results.
    Sorgi P; Ratey J; Knoedler DW; Markert RJ; Reichman M
    J Neuropsychiatry Clin Neurosci; 1991; 3(2):S52-6. PubMed ID: 1687961
    [No Abstract]   [Full Text] [Related]  

  • 15. The measurement of aggressive behavior: reflections on the use of the Overt Aggression Scale and the Modified Overt Aggression Scale.
    Ratey JJ; Gutheil CM
    J Neuropsychiatry Clin Neurosci; 1991; 3(2):S57-60. PubMed ID: 1821223
    [No Abstract]   [Full Text] [Related]  

  • 16. [Congenital long QT syndrome: an elective indication for betablocker treatment. Apropos of 5 cases].
    Hayoun B; Lupoglazoff JM; Magnier S; Denjoy I; Casasoprana A
    Arch Mal Coeur Vaiss; 1995 May; 88(5):737-42. PubMed ID: 7646286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nadolol in the treatment of aggression in chronic psychiatric inpatients.
    Wong MK; Lee S
    J Clin Psychiatry; 1993 Jun; 54(6):235. PubMed ID: 8331093
    [No Abstract]   [Full Text] [Related]  

  • 18. Pilot study evaluating the effect of massage therapy on stress, anxiety and aggression in a young adult psychiatric inpatient unit.
    Garner B; Phillips LJ; Schmidt HM; Markulev C; O'Connor J; Wood SJ; Berger GE; Burnett P; McGorry PD
    Aust N Z J Psychiatry; 2008 May; 42(5):414-22. PubMed ID: 18478478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.
    Fallu A; Richard C; Prinzo R; Binder C
    Curr Med Res Opin; 2006 Dec; 22(12):2557-66. PubMed ID: 17166338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.